**Post-Restructuring & Resolution Phase** Cian Healthcare Limited is an **ISO 9001:2015** and **WHO GMP** certified pharmaceutical company specializing in the manufacturing and marketing of a diverse range of dosage forms. Following a period of significant financial distress, the company is currently undergoing a transformative transition under an **NCLT-approved Resolution Plan** (ordered **December 18, 2025**). The company is being integrated into the ecosystem of **Ananta Medicare Limited**, led by **Mr. Pradeep Kumar Jain**, marking a shift from insolvency toward operational revival. --- ### Corporate Rebirth: The 2026 Resolution & Ownership Structure The company’s capital structure has been fundamentally reorganized to settle creditor claims and provide a clean slate for growth. Under the **Corporate Insolvency Resolution Process (CIRP)**, the following restructuring has been implemented: * **Capital Infusion:** The Successful Resolution Applicant (SRA) committed a **Total Bid Value of INR 37.30 Crore**. * **Equity Reorganization:** The paid-up capital has been restructured to **INR 25 Crore**. * **Extinguishment of Old Equity:** The **27.10%** stake (**67,74,897 shares**) previously held by erstwhile promoters was cancelled and extinguished to **Zero** without consideration. * **New Promoter Holding (95%):** A total of **2,37,50,000** fresh shares are held by: * **Ananta Medicare Limited:** **55%** (**1,37,50,000** shares) * **Mr. Rajesh Jain:** **21%** (**52,50,000** shares) * **Mr. Pradeep Kumar Jain:** **19%** (**47,50,000** shares) * **Public Shareholding (5%):** Existing public holdings were written down to **12,50,000** shares to maintain listing status. The company is committed to reaching **10% public float within 12 months** and **25% within 3 years**. --- ### Diversified Revenue Streams & Market Verticals Cian Healthcare operates through five distinct business pillars, providing a hedge against volatility in any single market segment: 1. **Third-Party / Contract Manufacturing:** The primary revenue driver (**₹24.64 Crore** in FY25). Key clients include industry leaders such as **Sun Pharmaceutical Industries Limited** and **Vivaldis Health and Foods**. 2. **Own Brand Franchise Business:** Marketing a robust portfolio under the **CIAN** brand, featuring over **600+ brands** and **200+ registered molecules**. 3. **Export Operations:** Direct and merchant exports to high-growth emerging markets including **Afghanistan, Benin, Bhutan, Bolivia, Cambodia, Sri Lanka, and Myanmar**. 4. **Government Supplies:** Strategic manufacturing for the **Pharmaceutical and Medical Device Bureau of India (PMBI)** and **HLL Lifecare Limited**. 5. **Specialized Partnerships:** A major agreement with **CHI Pharmaceuticals (Nigeria)** to shift production of five major product ranges from Korea to Cian’s Indian facilities. --- ### Manufacturing Infrastructure & Specialized Capabilities The company’s production backbone is centered in the pharmaceutical hub of Uttarakhand, with a newly established corporate presence in the capital. | Facility Type | Location | Strategic Importance | | :--- | :--- | :--- | | **Primary Factory** | Roorkee, Uttarakhand | **WHO GMP Certified**; handles tablets, capsules, soft gels, and liquid orals. | | **Subsidiary Plant** | Roorkee, Uttarakhand | Operated by **Dr. Smiths Biotech**; dedicated to cosmetics and toiletries. | | **Corporate Office** | Rohini, New Delhi | Shifted from Pune in **March 2026** to centralize management. | | **R&D Center** | Centralized Facility | Focused on **differentiated products** and controlled-release pharmaceuticals. | **Technical Expertise:** The facilities are equipped to handle products requiring strictly controlled humidity and temperature, essential for advanced **Nutraceuticals** and **Controlled-release** formulations. --- ### Comprehensive Product Portfolio & Therapeutic Reach Cian maintains a vast therapeutic footprint, allowing it to pivot based on seasonal and market demands: * **Core Therapeutic Areas:** Gynecology, Hematinic, Cardio-diabetic, Orthopedic, Pediatric, Derma-cosmetic, Antibiotic, CNS, and Vitamins/Nutrients. * **Dosage Form Versatility:** * **Orals:** Tablets, Capsules, Soft Gels, Liquid Orals, Sachets, and Dry Powders. * **Topicals:** Ointments, Creams, Medicated Soaps, and Shampoos. * **Advanced:** Injectables and Protein Powders. * **Strategic Expansion:** The company has recently prioritized the **Cosmetic manufacturing** sector to capitalize on surging domestic demand for specialized personal care. --- ### Financial Performance & Recovery Metrics The company is emerging from a period of severe financial contraction. The FY 2024-25 figures reflect the "bottoming out" phase prior to the full implementation of the resolution plan. | Financial Metric (Consolidated) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Total Revenue** | **₹31.14 Crore** | **₹59.81 Crore** | | **Profit / (Loss) After Tax** | **(₹19.65 Crore)** | **₹38.96 Lakh** | | **Earnings Per Share (EPS)** | **(₹10.39)** | **₹0.34** | | **Total Assets** | **₹142.68 Crore** | - | | **Admitted Creditor Claims** | **₹68.61 Crore** | - | **Recovery Allocation:** Of the resolution funds, **INR 15 Crore** has been earmarked for **Working Capital** and **INR 7 Crore** for **Capital Expenditure** to upgrade technology and machinery. --- ### Strategic Roadmap for Value Creation The new management has outlined a multi-pronged strategy to restore shareholder value: * **Operational Optimization:** Adoption of modern technology platforms and strengthening the supply chain to improve production efficiencies. * **Margin Expansion:** Shifting the product mix toward **high-margin, evidence-based formulations** and food supplements. * **Regulatory Compliance:** Restoring the company’s credit rating (previously **CRISIL D**) and resolving past statutory defaults related to PF, TDS, and Income Tax. * **Market Re-entry:** Re-applying for migration from the **BSE SME Platform** to the **BSE Main Board** once compliance criteria are met. --- ### Critical Risk Factors & Mitigation Investors should remain cognizant of the following challenges inherited from the insolvency period: * **Subsidiary Distress:** **Dr. Smiths Biotech Private Limited** was admitted to CIRP in **April 2025**; its operations are currently stalled, and the **₹7.09 Crore** investment is under scrutiny. * **Audit Disclaimers:** Statutory auditors issued a **Disclaimer of Opinion** for FY25, citing a lack of audit trails, discrepancies in inventory valuation (**₹25.62 Cr book value vs ₹18.69 Cr valuation**), and missing fixed asset registers. * **Quality Litigation:** Past issues regarding "below standard quality" products (e.g., Albendazole tablets) have caused reputational and financial strain. * **Statutory Demands:** Unpaid Income Tax demands of **₹3.85 Crore** remain under appeal. **Mitigation:** The **NCLT-approved Resolution Plan** provides a legal "clean slate" regarding many historical liabilities, and the infusion of **fresh capital** by Ananta Medicare is intended to address the negative working capital and operational lapses.